Everything you need to win Arbor Biotechnologies — in one platform.
Who to reach, what to say, and why now on Arbor Biotechnologies — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Arbor Biotechnologies — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Partnership: Arbor Biotechnologies Announces $73.9 Million Series C Financing
Mar 18, 2025•about 1 year ago
Contract Type
partnership
CambridgeBiotechnology
Description
Arbor Biotechnologies announced the closing of a $73.9 million Series C financing to support the advancement of its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system (CNS). The financing, led by ARCH Venture Partners and TCGX with significant participation from existing and new investors, will support clinical development of the company's lead therapeutic candidate, ABO-101, in primary hyperoxaluria type 1 (PH1) and progression to IND/CTA filing of its first-in-class programs.
Company Information
Company
Arbor Biotechnologies
Location
20 ACORN PARK DRIVE
Cambridge, Massachusetts, United States
About
Arbor Bio is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry. We have the unique ability to work backward from disease pathology and choose the optimal editors or combination of editors for the disease in question.
CambridgeBiotechnology